title: [Ablative Radioiodtherapie bei niedrigem und intermediärem Rezidivrisiko. Höhere Überlebensrate beim Schilddrüsenkarzinom].
authors.affiliation: Prof. Dr. Markus Dietlein, Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Köln, Kerpener Str. 62, 50937 Köln, Tel. 02 21/478 50 24, markus.dietlein@uk-koeln.de.
authors.forename: Markus
authors.initials: M
authors.lastname: Dietlein
authors.forename: Alexander
authors.initials: A
authors.lastname: Drzezga
mesh_terms: D015897:Comorbidity; D019317:Evidence-Based Medicine; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000517:prevention & control*; D015995:Prevalence; D011832:Radiation Injuries / Q000401:mortality* / Q000517:prevention & control; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000401:mortality* / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals